ABOUT THIS PODCAST
This podcast will provide members with analysis of the Administration’s actions on drug pricing to date, including proposed tariffs and two separate Executive Orders (EOs). We’ll talk through key elements of the EO on Most Favored Nation pricing, how it might intersect with the earlier, more general EO on drug pricing, and what these policy shifts could mean for members. We’ll also discuss how potential tariffs on pharmaceuticals might further complicate the drug pricing picture.
SPEAKERS
- Jillanne Schulte Wall, Senior Director, Health & Regulatory Policy
ASHP - Tom Kraus, Vice President, Government Relations
ASHP
